Friday, November 1, 2024

CATEGORY

Johnson & Johnson

Johnson & Johnson Advances AFib Care with OMNY-AF Trial and Innovative OMNYPULSE Platform

Key TakeawaysEmbrace diverse evidence synthesis techniques to enhance the quality of JCA dossiers. Recognize the importance of ITCs in addressing gaps left by...

Johnson & Johnson’s New Data Highlights Promising Neuropsychiatry Advances

Johnson & Johnson continues to blaze a trail in the field of neuroscience, reinforcing its commitment to addressing complex mental health challenges through innovation....

TREMFYA® Achieves Remarkable Outcomes in Treating Crohn’s Disease and Ulcerative Colitis

Key TakeawaysTREMFYA® (guselkumab) has shown superior efficacy in inducing remission for both biologic-naïve and biologic-refractory patients with Crohn's disease (CD) and ulcerative colitis...

Nipocalimab Demonstrates Sustained Disease Control in Adolescents with Generalized Myasthenia Gravis (gMG) in Phase 2/3 Study

Key TakeawaysNipocalimab, a first-of-its-kind FcRn blocker, shows sustained disease control in adolescents with generalized myasthenia gravis (gMG) over 24 weeks. Adolescents (ages 12-17)...

Johnson & Johnson MedTech Unveils VOLTâ„¢ Plating System for Enhanced Fracture Care

Key TakeawaysVOLTâ„¢ Plating System offers next-generation fracture management with improved stability, flexibility, and performance for orthopedic procedures. The system provides a wide array...

Multiple Myeloma Treatment Advances: CARVYKTI® Shows Significant Survival Benefits in Lenalidomide-Refractory Patients

Key TakeawaysCARVYKTI® significantly improves overall survival in multiple myeloma patients. The treatment shows a 45% reduction in the risk of death compared to...

Multiple Myeloma Treatment Advances: CEPHEUS Study Highlights Promising Results for D-VRd Regimen

Key TakeawaysThe Phase 3 CEPHEUS study demonstrated that the D-VRd regimen significantly improves MRD negativity rates, progression-free survival, and complete response rates in...

Multiple Myeloma Treatment Advancements: Promising Results from TALVEY® and TECVAYLI® Combination Therapy

Key TakeawaysThe combination of TALVEY® and TECVAYLI® demonstrated high response rates and durable responses in relapsed or refractory multiple myeloma patients. Especially effective...

DARZALEX® Receives Positive CHMP Opinion for Newly Diagnosed Myeloma

Key TakeawaysDARZALEX® quadruplet regimen reduces risk of progression or death by 60% in newly diagnosed multiple myeloma patients. The positive CHMP opinion marks...

Johnson & Johnson’s Subsidiary Files for Bankruptcy to Resolve Ovarian Cancer Talc Claims

Key TakeawaysRed River Talc LLC, a Johnson & Johnson subsidiary, has filed for a prepackaged Chapter 11 bankruptcy to address ovarian cancer claims. ...

Lung Cancer Breakthrough: FDA Approves Rybrevant for EGFR Mutated Non-Small Cell Lung Cancer

Key TakeawaysThe FDA has approved Rybrevant in combination with chemotherapy for the treatment of EGFR-mutated NSCLC, targeting patients whose disease progressed after TKI...

RYBREVANT® Plus Chemotherapy Shows Positive Survival Trend in EGFR-Mutated Lung Cancer

Key TakeawaysThe MARIPOSA-2 study shows a positive overall survival trend for RYBREVANT® (amivantamab-vmjw) plus chemotherapy versus chemotherapy alone in EGFR-mutated non-small cell lung...

RYBREVANT® Plus Chemotherapy Shows 49% Response in Metastatic Colorectal Cancer

Key TakeawaysRYBREVANT® (amivantamab-vmjw) combined with chemotherapy shows a 49% overall response rate in metastatic colorectal cancer (mCRC). Patients achieved a median duration of...

Shockwave Medical Expands Peripheral IVL Portfolio with E8 Catheter

Key TakeawaysThe Shockwave E8 catheter enhances treatment options for Peripheral Arterial Disease (PAD), especially in calcified lesions above and below the knee. The...

TAR-200 Plus Cetrelimab Doubles Response in Muscle-Invasive Bladder Cancer

Key TakeawaysTAR-200 with cetrelimab nearly doubles the pathological complete response (pCR) rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer (MIBC). ...

Latest news